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Antibody-mediated inhibition of Epstein-Barr virus (EBV) release from the EBV-productive cell lines
P3HR-1 and B95-8 was probed with two monoclonal antibodies (MAbs), 72A1 and 2L10, which immunopre-
cipitated the same EBV membrane antigen (MA) gp350/220 found with the 1B6 MAb with which inhibition of
EBV release from P3HR-1 cells was first described. These three MAbs were not equivalent in either MA
reactivities or functional effects, reflecting the variable expression of different epitopes of gp350/220. 1B6
recognized MA on P3HR-1 cells, which expressed predominately the gp220 form of MA. 1B6 did not recognize
(or barely recognized) a determinant on B95-8 cells. MAbs 2L10 and 72A1 reacted as well with B95-8 cells as
they did with P3HR-1 cells. MAbs 1B6 and 2L10 neutralized neither P3HR-1 nor B95-8 virus, but 72A1
neutralized both viruses. MAbs 1B6 and 72A1 inhibited P3HR-1 virus release, as measured by the assay for
infectious virus and by DNA hybridization analysis of released virus, but 2L10 had no such activity. 72A1 (but
not 1B6) inhibited release of EBV from B95-8 cells. These experiments pointed to the presence of three different
epitopes on gp350/220, identified with the respective MAbs and having varying involvement in virus
neutralization and virus release inhibition.
We seek to define the functions of Epstein-Barr virus
(EBV)-determined membrane antigens (MA) and anti-MA
antibodies on the EBV cycle and in immune defense against
EBV infections. MA is a general term which applies to
several EBV-induced membrane proteins, including, at
least, those of molecular weights 350,000 (gp350), 220,000
(gp220, from an alternately spliced mRNA of the gp350
gene), 140,000 (p140), and 85,000 (gp85) (1, 3, 9, 17). On cell
surfaces, these MA can be targets for antibody-dependent
cellular cytotoxicity (22) or complement-mediated cytotox-
icity (30). On viral envelopes, they can be targets for
virus-neutralizing antibodies (33). Additionally, a monoclo-
nal antibody (MAb), 1B6, to gp350/220 was found not to
neutralize infectious EBV but yet blocked the release of
EBV from the EBV-producing cell line P3HR-1 (28).
In the current study, we have further analyzed the effects
of MAb 1B6 and two additional anti-gp350/220 MAbs, 72A1
(8) and 2L10 (11), on inhibition of virus release from two
EBV-producing cell lines, P3HR-1 (7) and B95-8 (15). P3HR-
1 cells produce a virus which is nontransforming and early
antigen (EA) inducing (16), and they synthesize predomi-
nately gp220 rather than gp350 (3, 19). In contrast, B95-8
cells produce transforming virus (15), and their expression of
gp350 is much greater than that of gp220 (3, 19). gp350 and
gp220 appear to mediate virus attachment to the CR2 recep-
tor, a form of complement receptor that binds the C3d
component of complement on EBV-infectable cells (18, 31).
We have found that these MAbs have variable reactivities
against MA and variable functional effects in terms of
inhibiting virus release from EBV-producer cell lines and of
virus neutralization. EBV release inhibition was analyzed
not only by functional indicator assays (EA-inducing activity
for P3HR-1 EBV and transforming activity for B95-8 EBV)
* Corresponding author.
but also by EBV virion genome hybridization. These results
have been interpreted to reflect the roles of various gp350/
220 epitopes in virus neutralization and in release of EBV
from productive cells.
MATERIALS AND METHODS
Medium and cell lines. RPMI 1640 medium (GIBCO,
Grand Island, N.Y.) with streptomycin (100 ,ug/ml) and
penicillin (100 IU/ml) was supplemented with 10% fetal calf
serum. Raji, an EBV-nonproducer cell line (21), was the
target for a quantitative superinfection assay of EBV from
the P3HR-1 cell line (7). Two EBV-producer cell lines,
P3HR-1 and B95-8 (15), passaged at 33°C (25) and 37°C,
respectively, were used to assay virus production during
culture with various MAbs.
MAbs. The derivation and some functional characteristics
ofMAb 1B6 have been described (28). MAb 72A1 (8) was the
gift of G. J. Hoffman, Johns Hopkins University, Baltimore,
Md., and D. A. Thorley-Lawson, Tufts University, Boston,
Mass. MAb 2L10 (11) was the gift of G. R. Pearson,
Georgetown University, Washington, D.C. MAb Cl (32)
was the gift of D. A. Thorley-Lawson. All MAbs were of the
immunoglobulin G (IgG) class.
Virus preparations and quantitation of infectious virus.
P3HR-1 EBV was concentrated from supernatants of P3HR-
1 cell cultures after 14 days at 33°C (28). B95-8 EBV was
obtained from supernatants of cultures maintained for 7 days
at 37°C (15). The procedures for virus preparations in the
MAb-mediated EBV release inhibition assays are described
in Results. Infectivity of P3HR-1 EBV was assayed by viral
induction of EA in Raji target cells and was quantitated as
EA-inducing units (EAIU) per milliliter (24). Infectivity of
B95-8 EBV was assayed by transformation of human umbil-
ical cord blood lymphocytes (15) and quantitated as 50%
2614
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transforming units (TD50) per milliliter by the Reed-Muench
formula (26).
Neutralization assay. The P3HR-1 EBV neutralization as-
say quantitated inhibition, by a given dilution of antibody, of
the ability of a viral sample to induce EA expression upon
infection of Raji cells (20, 29). Mixtures of 0.2 ml of a virus
suspension (2 x 105 EAIU/ml) and 0.2 ml of a dilution of
heat-inactivated antibody were incubated for 60 min at 37°C.
Raji cells (0.1 ml; 107 cells per ml) were added for 90 min at
37°C to such virus-antibody mixtures or to a virus-medium
mixture, washed, and suspended at 106 cells per ml. The
infected cells were incubated at 37°C for 2 days. Acetone-
fixed smears of those cells were prepared for immunofluo-
rescent measurement of EA induction (6). A neutralization
index was calculated by the formula of Pearson et al. (20).
The neutralization assay for B95-8 EBV was modified
from the method of Miller et al. (14). Twofold serial dilutions
of MAb were prepared in culture medium. These solutions
(0.2 ml) were mixed with 0.2 ml of a virus suspension
containing 200 TD5dml and was held at 37°C for 1 h. The
MAb-virus mixture (0.1 ml) was added to human umbilical
cord blood lymphocytes (0.1 ml at 3 x 106 cells per ml) in
microtiter wells (plate no. 3596; Costar, Cambridge, Mass.).
Virus neutralization endpoints were read 42 days after
inoculation, and neutralization titers reflected the final dilu-
tion of MAb with some neutralizing activity.
Immunofluorescence assays. An indirect membrane immu-
nofluorescence (MIF) technique was used to assay MA (27).
Approximately 106 cells were pelleted and resuspended for
30 min at 37°C in appropriately diluted MAb. After being
washed with phosphate-buffered saline (PBS), the cells were
reacted for 30 min at 37°C with fluorescein isothiocyanate
(FITC)-labeled anti-mouse IgG (Organon-Teknika-Cappel,
Malvern, Pa.). After being washed with PBS, the cells were
suspended in 50% glycerol in PBS and placed under a cover
slip for examination with a fluorescence microscope. EA
was detected with a serum (anti-EA, 1:320; anti-VCA, 1:320)
from a patient with nasopharyngeal carcinoma. Viral capsid
antigen (VCA) was detected with a normal human serum
(anti-VCA, 1:160; anti-EA, less than 1:10). Cells were spot-
ted on a glass slide, dried, and fixed in acetone for 10 min at
room temperature. The fixed cells were incubated with a
drop of diluted antibody at 37°C for 30 min. After being
washed in PBS, the slides were treated with FITC-conju-
gated anti-human IgG (Organon-Teknika-Cappel) at 37°C for
30 min. The slides were washed in PBS, mounted in glycerol-
PBS (1:1) solution, and examined under a fluorescence
microscope.
Determination of MA forms. P3HR-1 or B95-8 cells, loga-
rithmically growing at 37°C, were cultured with 12-O-tetra-
decanol-phorbol-13-acetate (TPA; 20 ng/ml) (Sigma Chemi-
cal Co., St. Louis, Mo.) and n-butyrate (4 mM; Sigma) for 48
h (28). These cells (108) were [35S]methionine-labeled for 18
h, harvested by centrifugation, washed three times with cold
PBS, and suspended in 2 ml of ice-cold extraction buffer (10
mM Tris hydrochloride buffer [pH 7.2], 0.15 M NaCl, 0.02%
NaN3, 0.5% [wt/vol] Triton X-100, 10 mM N-ethylmalei-
mide, and 2 mM phenylmethylsulfonyl fluoride). After vor-
texing and sonication on ice, the undissolved material was
sedimented at 110,000 x g for 30 min. The supernatant fluid
was divided into 200-pul portions and stored at -80°C. For
immunoprecipitations, a portion was incubated (three times
for 15 min each on ice) with Affi-Gel 10 (100 pAl; Bio-Rad
Laboratories, Richmond, Calif.) coupled with goat anti-
mouse immunoglobulins antiserum (Organon-Teknika-
Cappel), and cleared by sedimentation of the beads at 12,000
x g for 90 s. The cleared supernatant was used for immu-
noprecipitations. Immunoadsorbants were prepared by cou-
pling affinity-purified goat anti-mouse IgG antibody (Orga-
non-Teknika-Cappel) to Affi-Gel 10, followed by incubation
(3 h, 4°C) with MAb (10 pI) plus 990 pl of 0.1 M HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buff-
er, pH 7.5. After being washed once with 0.5% Triton X-100
buffer (0.15 M NaCl, 5 mM EDTA, 50 mM Tris hydrochlo-
ride [pH 7.4], 0.02% sodium azide) and three times with
0.05% Triton X-100 buffer, antigen preparations were added
and rocked overnight at 4°C. The following day, after being
washed five times with 0.05% Triton X-100 buffer, antigen
was eluted by suspending the beads in 100 RI of sodium
dodecyl sulfate (SDS) sample buffer (62.5 mM Tris hydro-
chloride [pH 6.8], 10% [wt/vol] glycerol, 5% 2-mercaptoeth-
anol, 2.3% SDS). These samples and radiolabeled molecular
weight standards were subjected to SDS-polyacrylamide gel
electrophoresis (PAGE), and the gels were autoradio-
graphed.
Assay of EBV DNA by agarose gel electrophoresis. The
form and quantity of EBV DNA were determined by agarose
gel electrophoresis and genome hybridization of the blotted
electrophoretic patterns (5). Briefly, 106 cells or virus pellets
were suspended in 0.1 ml of sample buffer which contained
15% Ficoll and 0.01% bromophenol blue in 89 mM Tris-
borate buffer, pH 8.0, and loaded in vertical 0.75% agarose
gels. Lysis buffer (0.1 ml), containing 5% Ficoll, 1% SDS, 1
mg of pronase per ml, and 0.05% xylene cyanol green in 89
mM Tris-borate buffer, was layered over the sample. The
electrophoresis ran at 20 V for 2 h and then at 80 V for 18 h
at 4°C. The gels were stained with ethidium bromide, and
DNA in the gel was partially depurinated with 0.25 M HCl,
denatured in 0.5 M NaOH in 1.5 M NaCl, neutralized, and
blotted to a nitrocellulose filter in transfer buffer (0.5 M Tris
hydrochloride buffer, 1.5 M NaCl [pH 7.0]) under vacuum
(12). The papers were baked at 80°C for 1 h, treated with
prehybridization buffer, and hybridized with cloned EBV
DNA pBamHI-W plasmid (a generous gift of E. Kieff,
Harvard University, Cambridge, Mass.) which was labeled
by nick repair with [32P]dCTP. Each filter was washed five
times in 250 ml of 0.1x sodium citrate buffer (0.0015 M
sodium citrate, 0.015 M NaCl [pH 7.5])-0.1% SDS and
exposed to Kodak XAR film at -70°C.
RESULTS
Immunoprecipitation of gp350/220. Original publications
on MAbs 1B6, 72A1, 2L10, and Cl reported their target MA
molecules to be 200, 250, 200/250, and 350/220 kilodaltons,
respectively (8, 11, 28, 32). In our experiments, these MAbs
all recognized the same set of molecules, among which a
220-kilodalton protein predominated in P3HR-1 cells cul-
tured with TPA and n-butyrate (P3-T/B) (Fig. 1A). Also in
P3-T/B cells, minor components of about 350 kilodaltons and
160 kilodaltons were found. MA immunoprecipitations from
B95-8 cells were demonstrated with MAb 72A1 but not MAb
1B6 (Fig. 1B). MAb 72A1 immunoprecipitated principally a
350-kilodalton MA molecule, and a 220-kilodalton MA was
present as a minor component.
Comparison of anti-MA MAb reactivities on P3HR-1 and
B95-8 cells. The MIF reactivities of MAbs 1B6, 72A1, and
2L10 were compared on P3-T/B cells and on B95-8 cells
(Table 1). Similar percentages (40 to 50%) of MA' P3-T/B
cells were identified with each of these MAbs. With these
cells, no variations among the three MAbs were found in
terms of immunofluorescence patterns or intensities of reac-
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FIG. 2. P3HR-1 EBV neutralization with MAbs 1B6 (A), 72A1
(0), and 2L10 (A) and with EBV-seropositive human serum (0).
45
FIG. 1. SDS-PAGE of immunoprecipitates with MAbs 1B6,
72A1, 2L10, or Cl or normal mouse ascites (NMA), and
[35S]methionine-labeled cell extracts from TPA- and n-butyrate-
treated P3HR-1 (P3-T/B) (A) or B95-8 (B) cells. Positions of stan-
dards (in kilodaltons) are indicated with arrows. gp350, gp220, and
putative precursor p160 are indicated at the right.
tions. However, with B95-8 cells, in which gp350 was
predominantly expressed, 72A1 and 2L10 showed compara-
bly strong MIF staining of about 10% of cells, while 1B6
occasionally stained faintly only about 1 to 2% of the cells or
(usually) no cells. We concluded on the basis of these MIF
and immunoprecipitation experiments that each of these
three MAbs recognized gp350/220 but at two or more dif-
ferent epitopes.
Neutralization of P3HR-1 or B95-8 EBV with MAb. Neu-
tralization assays were performed with MAbs 1B6, 72A1,
and 2L10 and, as a control, with a human serum which had
neutralizing antibodies (Fig. 2). With P3HR-1 EBV, neutral-
izing activity was observed with 72A1 to a 1:320 dilution but
not at 1:640, and neutralization was seen with the human
serum to a 1:320 endpoint. No neutralization of P3HR-1
EBV was observed at any dilutions of 1B6 or 2L10 tested.
With B95-8 EBV, neutralizing activity was observed with
72A1 at a 1:320 dilution but not at a 1:640 dilution (Table 2).
No neutralization of B95-8 EBV was observed with 1B6 or
2L10. The findings of neutralization of P3HR-1 and B95-8
EBV by 72A1, while 1B6 and 2L10 did not neutralize these
viruses, pointed to the existence of functionally distinct
epitopes on gp350/220.
MAb effects on EBV production by P3HR-1 cells. P3HR-1
cells (4 x 105 cells per ml) were cultured with various
dilutions (1:100, 1:400, 1:1,600, and 1:6,400) of each of the
MAbs at 33°C for 15 days (Fig. 3). The cell numbers (1.5 x
106 cells per ml) and viability (80%) of all cultures at 15 days
were comparable. The EA-inducing titers of P3HR-1 EBV in
the culture supematants were assayed (Fig. 3A). A control
culture without MAb had 3.7 x 105 EAIU/ml. All cultures
with 2L10 had viral titers similar to the control culture. The
1B6- or 72Al-containing cultures demonstrated an MAb
dose-dependent decrease in virus titers even to 1:6,400
dilution of either MAb. The percentages of EA' and VCA+
P3HR-1 cells were enumerated in all 15-day cultures (Fig.
3B). 2L10-treated cultures showed a slightly higher fre-
quency of EA' or VCA+ cells than did the control culture,
but 1B6- or 72Al-treated cultures showed the same fre-
quency ofEA' or VCA+ cells as did the control culture. The
mechanism of 1B6 restriction of EBV titers in culture
supernatants was shown previously to reflect an inhibition of
release of virus, which accumulated intracellularly in treated
cells and did not reflect virus neutralization, virus aggrega-
tion, or inhibition of virus replication (28). A possible
alternative mechanism was also evaluated for the neutraliz-
ing effect of 72A1.
P3HR-1 EBV-neutralizing activity of MAb 72A1. In con-
trast to 1B6, the 72A1 MAb was found to have neutralizing
TABLE 1. Summary of MAb characteristics
MA reactivity' MA antibody titer Neutralizing activity (titer) Virus release-inhibitingactivity
MAb
P3HR-1 B95-8 P3HR-1 B95-8 P3HR-1 B95-8 P3HR-1 B95-8
cells cells cells cells EBV EBV cells cells
1B6 ++++ 1:163,840 NDb <1:20 <1:20 + -
72A1 ++++ ++++ 1:5,120 1:10,240 1:320 1:320 + +
2L10 ++++ ++++ 1:81,920 1:20,480 <1:20 <1:20 - ND
a Maximal intensity of MIF determined at antibody excess. P3-T/B cells were used for the MIF assays.
b ND, Not done.
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FIG. 3. Effect of MAbs on EBV production by P3HR-1 cells.
P3HR-1 cells were cultured with various dilutions of MAbs 1B6,
72A1, and 2L10 or without MAb (control) at 33°C for 15 days. (A)
Infectious EBV titers in culture supernatants. (B) Frequency of
EBV antigen-positive cells (A, EA; A, VCA).
TABLE 2. Neutralization of B95-8 EBV with MAbs
Final MAb No. transformed/3 wells inoculated'
dilution 1B6 72A1 2L10
1:20 3 0 3
1:40 3 0 3
1:80 3 0 3
1:160 3 2 3
1:320 3 2 3
1:640 3 3 3
1:1,280 3 3 3
a Number of wells transformed at 42 days per three wells inoculated per
MAb.
activity for P3HR-1 EBV (8, 14). However, this neutralizing
activity was observed only to a maximal dilution of 1:320
(Fig. 2), while supernatant production of virus was inhibited
even at MAb dilutions of 1:1,600 and 1:6,400 (Fig. 3A). We
further confirmed that the inhibition of virus production at
high MAb dilutions was not an effect of virus neutralization,
by assay of the EBV virion DNA in the culture supernatants.
Assay for EBV DNA by agarose gel electrophoresis and
hybridization. The structure and quantity of intracellular
EBV genomes were assayed to test whether 72A1 might alter
intracellular replication of EBV in P3HR-1 cells at 33°C for
15 days. Extrachromosomal EBV DNA can be found in
virus-containing cells in two forms: episomal circular (C)
DNA and virion-associated linear (L) DNA (5). No differ-
ences were observed in quantities of L-DNA between con-
trol and 72A1-treated cells (Fig. 4A). The mechanism for
decreased titers of infectious extracellular EBV cannot be
explained by inhibition of intracellular virus replication with
72A1.
Next, the amount of virion DNA in culture supernatants
was assayed quantitatively to determine whether the low
amount of virus was due to inactivation of viral infectivity or
inhibition of virus release (Fig. 3). A significantly lower
amount of EBV DNA was observed in preparations from
cultures treated with 1B6 or 721A but not with 2L10 than in
the control culture (Fig. 4B). These hybridization experi-
ments correlated with the titers of infectious virus (Fig. 3A).
A
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FIG. 4. EBV DNA analyzed by agarose gel electrophoresis. (A) Intracellular EBV DNA from P3HR-1 cells cultured with MAb 72A1 or
control ascites for 15 days at 33°C. Cells (106) were loaded in the well of an agarose gel, lysed, subjected to electrophoresis, and blotted to
nitrocellulose filters for EBV DNA hybridization. Lanes 1 and 2 show EBV DNA bands from cells cultured with 1:100 and 1:400 dilutions
of MAb or control ascites, respectively. C, Circular EBV DNA. L, Linear EBV DNA. (B) Virion-derived L-DNA in supernatants of the
MAb-treated P3HR-1 cells presented in Fig. 3. The supematants were centrifuged at 5,000 x g for 10 min to remove cellular debris, and the
supernatants (3 ml) were centrifuged at 53,000 x g for 60 min. The virus pellet was suspended in 200 ,ll of sample buffer, and 100 ,ul of that
suspension was loaded into a well. Lanes 1, 2, 3, and 4 show L-DNA from culture fluids at 1:100, 1:400, 1:1,600, and 1:6,400 dilutions ofMAb,
respectively. Lane C, Control without MAb. Lane P3, P3HR-1 cells at 33°C to show the migration of C- and L-DNA.
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One could also propose that 72A1 might not only neutral-
ize the EBV but also lead, directly or indirectly, to degra-
dation of the DNA of the MAb-reacted virus over a 10-day
period of incubation. To test this possibility, 0.1 ml of EBV
(2.7 x 105 EAIU/ml) and 0.1 ml of MAb dilutions were
incubated at 33°C for 10 days, and EBV virion DNA was
assayed by gel electrophoresis and hybridization (Fig. 5A).
Although infectious titers of EBV decreased to an unquan-
titatable level (<103 EAIU/ml) during the incubation and the
degree of hybridization was lessened by the incubation
relative to that in the unincubated control, perhaps due to a
degradative process, the amount of EBV genome detected
by hybridization was uniform during the period of incubation
with 1B6 or 72A1 (Fig. 5A). These data supported the view
that EBV release from P3HR-1 cells was inhibited by 1B6
and 72A1 but not by 2L10.
Inhibition of EBV release from B95-8 cells by 72A1 but not
1B6. B95-8 EBV cells were cultured with 1B6 or 72A1 (1:
1,000 or 1:10,000 dilution) for 5 days at 37°C without effect
on cell growth (data not shown). The transforming titers of
infectious virus in the supematants were significantly de-
creased by 72A1 at a 1:1,000 dilution and slightly decreased
at a 1:10,000 dilution relative to control cultures (Table 3).
No effect was seen in the 1B6-treated cultures. A more
detailed analysis of the effect of 72A1 dilution on inhibition
of virus release was performed (Fig. 6). In this experiment,
72A1 inhibited virus release significantly at a dilution of 1:
A 1 86 _72AI
_____~ ~ ~ ~ ~~~~~~~__
C 1 2 3 4 1 2 3 4 P3HR-1
345
d-
FIG. 5. Effect of incubation of virus and MAb on EBV virion.
P3HR-1 (A) or B95-8 (B) EBV was incubated at 33°C for 10 days or
at 37°C for 5 days, respectively, with various dilutions of MAb 1B6
or 72A1. Virion DNA was assayed by hybridization after agarose gel
electrophoresis. Lanes C, EBV stored at -70°C without subsequent
incubation. Lanes 1, 2, 3, 4, and 5, L-DNA incubated with 1:100, 1:
400, 1:1,600, 1:6,400, and 1:25, 600 dilutions of MAb, respectively.
P3HR-1 or Raji cells were used to show the positions of C- and
L-DNA.
TABLE 3. Inhibition of B95-8 EBV production with MAbsa
MAb MAb dilution TD50ml
Control (ascites) 1:1,000 W.3
1: 10,00 104.0
1B6 1:1,000 .3
1:10,00 104.0
72A1 1:1,000 <100 8
1: 10,000o3.5
a B95-8 cells were cultured with medium containing MAb (1:1,000 or
1:10,000) for 5 days at 37°C, and the infectivity of supernatants was assayed
by the transformation assay (14).
6,400. Since the neutralizing activity of 72A1 was 1:320
(Table 2), one can conclude that the effect of greater dilu-
tions of 72A1 on extracellular virus titers did not reflect virus
neutralization.
Intracellular viral DNA was assayed by agarose gel elec-
trophoresis and hybridization. We saw no effect of 72A1 on
the production of intracellular viral genomes (Fig. 7A).
Antibody-treated cultures were tested for the amount of
virion DNA in the culture supernatant (Fig. 7B). MAb 72A1
treatment decreased significantly the amount of hybridized
EBV DNA at 1:1,000 and slightly at 1:10,000 dilutions of
MAb. No effect was seen with 1B6 compared with control
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FIG. 6. Effect of MAb 72A1 on infectious EBV production by
B95-8 cells. The cells were cultured with various dilutions of72A1 at
37°C for 5 days. Infectious EBV was assayed in the supernatants by
the transformation assay (14). C, Control culture without MAb.
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FIG. 7. Effects of MAbs on EBV production by B95-8 cells.
B95-8 cells were cultured with various dilutions ofMAb 1B6 or 72A1
or without MAb (control) at 37°C for 5 days. The form and quantity
of EBV genomes were assayed by EBV genome hybridization with
(A) cells and (B) culture supernatants. The cells were cultured with
medium containing control ascites at 1:1,000 (lanes 1) or 1:10,000
(lanes 2); 1B6 at 1:1,000 (lanes 3) or 1:10,000 (lanes 4); or 72A1 at 1:
1,000 (lanes 5) or 1:10,000 (lanes 6). Lane 7, Raji cells with only
C-DNA. Lane 8, P3HR-1 cells with both L- and C-DNA forms.
cultures. As in the case of P3HR-1 EBV, a possible effect of
72A1 in degrading EBV genome was tested (Fig. SB). B95-8
EBV DNA was not decreased during a 5-day incubation at
37°C with 72A1, as was also the case in similar studies with
1B6. These data supported the view that EBV release from
B95-8 cells was inhibited by 72A1 but not by 1B6.
DISCUSSION
Our objective has been to describe mechanisms by which
antibodies to MA control EBV infections. Our focus has
been on EBV release-inhibiting antibodies which might play
a role in EBV infections to block the spread of virus (28). We
first described the EBV release-inhibiting phenomenon
through the use of MAb 1B6, which did not neutralize EBV.
Having established the basic biological process with infec-
tious-virus assays of EBV release inhibition, we turned to
the EBV genomic hybridization assay to quantitate EBV
virion DNA to rule out mechanisms of neutralization at
release. These biological and genomic analytical methods
have now been applied to a comparative study of other
MAbs to MA to look for: (i) various functional epitopes on
the MA, (ii) differences in MAb effects on different EBV-
producer cell lines and viruses, and (iii) distinctions among
antibodies in virus release inhibition and neutralization.
Three MAbs, 1B6, 72A1, and 2L10, were defined with
immunoprecipitation assays to recognize the same gp350/220
MA, although the original reports on 1B6 (28), 72A1 (8), and
2L10 (11) MAbs identified MA molecules of 200, 250, and
200/250 kilodaltons, respectively. SDS-PAGE of these im-
munoprecipitates from P3HR-1 cells showed a strong band
at 220 kilodaltons and fainter bands at 350 and 160 kilodal-
tons. It is known that the 350-kilodalton form of gp350/220 is
weakly expressed on P3HR-1 cells (1, 3) and that a p160 is a
nonglycosylated precursor of gp220 (4). These molecules
were also identified in immunoprecipitates with Cl, which
had been characterized to recognize gp350/220 (32). With
B95-8 cells, 72A1 immunoprecipitated a protein of 350
kilodaltons as the major band and a protein of 220 kilodal-
tons as a minor band; however, 1B6 appeared not to immu-
noprecipitate any protein. We concluded that these four
MAbs recognized the same gp350/220 MA.
MAbs 1B6, 72A1 and 2L10 appeared in immunoprecipita-
tion, immunofluorescence, neutralization, and virus release
inhibition studies to recognize different epitopes on gp350/
220. As summarized in Table 1, the three MAbs reacted
equally, in terms of MIF staining patterns and intensities, to
P3HR-1 cells, which expressed mainly the gp220 form (Fig.
1A). However, on B95-8 cells, which expressed predomi-
nantly gp350 (Fig. 1B), 1B6 stained faintly sometimes or not
at all, while 72A1 and 2L10 reacted strongly and as well as
they did on P3HR-1 cells. In EBV neutralization assays,
72A1 neutralized P3HR-1 EBV, while 1B6 and 2L10 did not.
Likewise, 72A1 neutralized B95-8 EBV, while no neutrali-
zation was observed with 1B6 or 2L10. 72A1 mediated EBV
release inhibition of both P3HR-1 and B95-8 EBV. 1B6
mediated P3HR-1 EBV release inhibition but not B95-8 EBV
release inhibition. 2L10 was negative in P3HR-1 EBV re-
lease inhibition assays. These results supported the conclu-
sion that specific functional epitopes on gp350/220 mediated
virus neutralization and/or inhibition of EBV release.
The negligible 1B6 MIF staining of B95-8 cells, its lack of
immunoprecipitation of B95-8 gp350/220, and its failure to
inhibit release of or neutralize B95-8 EBV were consistent
with the view that 1B6 recognized an epitope expressed on
the gp220 of P3HR-1 cells but not of B95-8 cells. One might
expect that the 1B6-recognized epitope has some conforma-
tion- or glycosylation-dependent component that is absent or
masked in B95-8 cells, since the primary amino acid se-
quence of gp220 is included in gp350 and genomic MA
sequences for P3HR-1 and B95-8 gp350/220 appear to be
identical (1, 9), and because 1B6 gave a weakly positive MIF
reaction with some preparations of B95-8 cells.
Demonstration of EBV release inhibition by 72A1, in the
face of its neutralizing capacity, depended on its significantly
higher titer for EBV release inhibition than for EBV neutral-
ization. 72A1 neutralized both P3HR-1 and B95-8 EBVs to a
dilution of 1:320. If one were considering a potential neutral-
izing activity of 72A1 in cultures tested for inhibition of EBV
release, potential neutralizing titers must be decreased by
absorption of a large portion of the neutralizing MAb to
MA' cells in the assay. Thus, even though 72A1 had a
neutralizing activity for P3HR-1 and B95-8 EBVs, we con-
cluded that 72A1 also had EBV release-inhibiting activity for
each EBV-producer cell line. This view was strengthened by
hybridization assays for virion DNA in culture supernatants.
MAb dose-dependent decreases in levels of virion DNA
were found in supernatants of 72A1-treated P3HR-1 and
B95-8 cell cultures (Fig. 4B and 7B). This assay for EBV
DNA further confirmed the view of antibody-mediated EBV
release inhibition which had been first demonstrated with the
infectious virus assay (28).
72A1 release inhibition of B95-8 EBV was more sharply
titrated than was its release inhibition of P3HR-1 EBV. In
the case of P3HR-1 cells, 72A1 (and 1B6) decreased the
supernatant virus titer from 1/10 to 1/50 of control levels but
never completely eliminated infectious virus from the super-
natants, even at high MAb concentrations (Fig. 3A). On the
other hand, 72A1 completely eliminated infectious virus
from supernatants of B95-8 cells at an MAb dilution of 1:100
and showed a dose-dependent inhibition of virus release to a
dilution of 1:25,600 (Fig. 6). These patterns of release
inhibition as a function of MAb dilution were confirmed in
direct genomic assays (Fig. 4B and 7B). The differences
between P3HR-1 and B95-8 cells might reflect differences in
the viruses of those cell lines (2, 23). P3HR-1 cells contain
unique, defective virions which are maintained by cell-to-
cell spread and can activate the latent EBV genome (13).
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However, B95-8 cells were observed to lack such defective
virion molecules, which are associated with the P3HR-1
heterologous DNA (10). In addition, since different culture
conditions were used for antibody treatments of the two cell
lines (15 days at 33°C for P3HR-1 and 5 days at 37°C for
B95-8), destruction of antibody activity or of EBV-con-
taining cells could contribute to this apparent difference in
the mechanism of antibody-mediated EBV release inhibi-
tion. Additionally, functional differences in release inhibition
might exist for the two principal MA forms, gp350 on B95-8
cells and gp220 on P3HR-1 cells.
Since gp350/220 mediates attachment of EBV to CR2 for
internalization of EBV (18, 31), one might ask whether
gp350/220 also plays a role in trafficking newly synthesized
virus for release. Structural differences in gp350/220, for
example, those induced by proteolysis or glycosylation,
might determine the function of those glycoproteins in virus
trafficking and release. The findings that gp350/220 is the
target for MAbs which inhibit EBV release and that multiple
epitopes on gp350/220 have variable roles in EBV release
inhibition and neutralization increase our understanding of
the molecular basis for MA functions.
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